Advertisement
Table 1 Baseline characteristics of individuals with rheumatoid arthritis in Quebec in 2002–2006 and 2007–2011
| Variables | 2002–2006 | 2007–2011 | ||||
|---|---|---|---|---|---|---|
| Anti-TNF (557) | DMARDs (1144) | Non-users (656) | Anti-TNF (690) | DMARDs (1651) | Non-users (532) | |
| Demographics | ||||||
| Age (mean (±SD)) years | 63.0(11.5) | 64.2 (10.8) | 65.1 (10.6) | 65.2 (10.5) | 66.2 (9.7) | 68.4 (9.3) |
| Sex (female N (%)) | 426 (76.5) | 921 (80.5) | 562 (85.7) | 517 (74.9) | 1281 (77.6) | 426 (80.1) |
| Residence (urban N (%)) | 428 (76.8) | 899 (78.6) | 526 (80.2) | 531 (77.0) | 1316 (79.7) | 425 (79.9) |
| Higher incomea | 344 (61.8) | 691 (60.4) | 379 (57.8) | 417 (60.4) | 980 (59.4) | 339 (63.7) |
| Socioeconomic status N (%) | ||||||
| Social quintile 0 | 58 (10.4) | 90 (7.9) | 48 (7.3) | 49 (7.1) | 100 (6.1) | 25 (4.7) |
| Social quintile 1 | 106 (19.0) | 211 (18.4) | 88 (13.4) | 113 (16.4) | 285 (17.3) | 74 (13.9) |
| Social quintile 2–3 | 192 (34.5) | 392 (34.3) | 238 (36.3) | 251 (36.5) | 618 (37.4) | 218 (41.0) |
| Social quintile 4–5 | 201 (36.1) | 451 (39.4) | 282 (43.0) | 276 (40.0) | 648 (39.2) | 215 (40.4) |
| Use of health services in prior year N (%) | ||||||
| Visit to rheumatologist | 490 (88.0) | 946 (82.7) | 480 (73.2) | 608 (88.1) | 1365 (82.7) | 338 (63.5) |
| Comorbidity in prior year N (%) | ||||||
| Hematologic disorders | 75 (13.5) | 112 (9.8) | 69 (10.5) | 72 (10.4) | 182 (11.0) | 69 (13.0) |
| Heart failure | 16 (2.9) | 29 (2.5) | 9 (1.4) | 19 (2.8) | 38 (2.3) | 23 (4.3) |
| Cerebrovascular disease | 21 (3.8) | 23 (2.0) | 19 (2.9) | 10 (1.4) | 39 (2.4) | 22 (4.1) |
| Atrial fibrillation | 14 (2.5) | 24 (2.1) | 13 (2.0) | 23 (3.3) | 54 (3.3) | 18 (3.4) |
| Ischemic heart disease | 79 (14.2) | 138 (12.1) | 76 (11.6) | 65 (9.4) | 186 (11.3) | 56 (10.5) |
| Peptic ulcer disease | 7 (1.3) | 10 (0.9) | 5 (0.8) | 1 (0.1) | 9 (0.5) | 3 (0.6) |
| Cancer | 39 (7.0) | 102 (8.9) | 51 (7.8) | 69 (10.0) | 172 (10.4) | 64 (12.0) |
| Medication use in prior year N (%) | ||||||
| NSAIDs | 430 (77.2) | 843 (73.7) | 452 (68.9) | 435 (63.0) | 980 (59.4) | 248 (46.6) |
| Serotonin reuptake inhibitors | 57 (10.2) | 107 (9.4) | 62 (9.5) | 71 (10.3) | 164 (9.9) | 532 (9.6) |
| Gastroprotective agents | 322 (57.8) | 664 (58.0) | 345 (52.6) | 463 (67.1) | 970 (58.8) | 328 (61.7) |
| Antidiabetics | 63 (11.3) | 115 (10.1) | 51 (7.8) | 81 (11.7) | 170 (10.3) | 77 (14.5) |
| Corticosteroid | 414 (74.3) | 757 (66.2) | 400 (61.0) | 500 (72.5) | 928 (56.2) | 306 (57.5) |
| Anticoagulants | 27 (4.8) | 49 (4.3) | 31 (4.7) | 32 (4.6) | 106 (6.4) | 34 (6.4) |
| Antihypertensives | 294 (52.8) | 587 (51.3) | 305 (46.5) | 414 (60.0) | 944 (57.2) | 335 (63.0) |
